Please ensure Javascript is enabled for purposes of website accessibility

Why BioNTech Shares Are Falling Today

By Keith Speights - Updated Jun 23, 2020 at 12:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

News of increased competition appears to be behind the biotech's sell-off.

What happened

Shares of BioNTech (BNTX -1.83%) were falling 7.3% as of 11:24 a.m. EDT on Tuesday. The German biotech didn't announce any news. The most likely reason behind the decline was that Sanofi (SNY 2.15%) is expanding its collaboration with Translate Bio (TBIO) to develop messenger RNA (mRNA) vaccines. The new deal between the two companies could be worth up to $1.9 billion.

So what

The expansion of the relationship between Sanofi and Translate Bio underscores the increased competition that is emerging in the arena of mRNA vaccines. Moderna is also developing mRNA vaccines, including a highly publicized COVID-19 vaccine.

Gloved hand holding COVID-19 vaccine syringe

Image source: Getty Images.

But the sell-off of BioNTech could be overdone. The company already has two big partners for its mRNA COVID-19 vaccine -- Pfizer and Chinese drugmaker Fosun Pharma. BioNTech has also teamed up with Pfizer, Genmab, and Roche on other mRNA programs.

In addition, BioNTech has a big head start with its COVID-19 vaccine compared to Translate Bio. While Sanofi and Translate Bio don't expect to advance their COVID-19 vaccine candidate into early-stage testing until the fourth quarter of 2020, BioNTech began a phase 1/2 clinical study of its COVID-19 vaccine in Germany in April with a U.S. clinical trial starting in early May.

Now what

The main thing to watch with BioNTech is the clinical progress for its COVID-19 vaccine candidate. BioNTech expects to report preliminary results from phase 1 studies by July. Positive news from these studies should provide a big catalyst for the biotech stock.

Keith Speights owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
BNTX
$159.50 (-1.83%) $-2.98
Sanofi Stock Quote
Sanofi
SNY
$44.77 (2.15%) $0.94
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.78 (0.06%) $0.03
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$41.54 (-1.74%) $0.74
Translate Bio, Inc. Stock Quote
Translate Bio, Inc.
TBIO
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$168.61 (-4.62%) $-8.17
Genmab A/S Stock Quote
Genmab A/S
GMAB
$36.24 (-2.69%) $-1.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.